Aytu Biopharma (AYTU) Change in Account Payables (2014 - 2026)

Aytu Biopharma (AYTU) has reported Change in Account Payables for 10 consecutive years, with -$1.0 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Change in Account Payables fell 362.56% year-over-year to -$1.0 million in Q1 2026; TTM through Mar 2026 was -$1.8 million, a 198.17% decrease from a year earlier, with the FY2025 full-year figure at $287000.0, up 113.82% from the prior year.
• Change in Account Payables was -$1.0 million for Q1 2026 at Aytu Biopharma, up from -$1.1 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.6 million in Q1 2023 and troughed at -$4.8 million in Q1 2022.
• A 5-year average of -$245058.8 and a median of $134000.0 in 2024 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables surged 232.24% in 2024 and slumped 1174.63% in 2025, its largest moves.
• Over 5 years, Change in Account Payables stood at -$4.4 million in 2022, then rose by 9.42% to -$4.0 million in 2023, then surged by 54.74% to -$1.8 million in 2024, then jumped by 40.3% to -$1.1 million in 2025, then climbed by 3.51% to -$1.0 million in 2026.
• The last three Change in Account Payables figures came in at -$1.0 million (Q1 2026), -$1.1 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.